Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens

Frontiers in Immunology

Volumn 2, Issue DEC, 2011, Pages

  Keskin, Derin B ^a,b   Reinhold, Bruce ^a,b   Lee, SunYoung ^c   Zhang, Guanglan ^a,b   Lank, Simon ^d   O'Connor, David H ^d   Berkowitz, Ross S ^a,b,e   Brusic, Vladimir ^a,b   Kim, Seung Jo ^c   Reinherz, Ellis L ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CHA University   (South Korea)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CTL targets; E7; GILT; Human papilloma virus; Mass spectrometry; T cell epitopes; T cell vaccines; Tumor antigens

Indexed keywords

EID: 84874022587     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2011.00075     Document Type: Article

References (61)

1. Alani, R. M., and Munger, K. (1998). Human papillomaviruses and associated malignancies. J. Clin. Oncol. 16, 330-337.
2. An, H. J., Cho, N. H., Lee, S. Y., Kim, I. H., Lee, C., Kim, S. J., Mun, M. S., Kim, S. H., and Jeong, J. K. (2003). Correlation of cervical carcinoma and precancerous lesions with human papillomavirus(HPV)geno-types detected with the HPV DNA chip microarray method. Cancer 97, 1672-1680.
3. Bae, J. H., Lee, S. J., Lee, A., Park, Y. G., Bae, S. N., Park, J. S., and Namkoong, S. E. (2008). Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer. Gynecol. Oncol. 111, 444-448.
4. Bambini, S., and Rappuoli, R. (2009). The use of genomics in microbial vaccine development. Drug Discov. Today 14, 252-260.
5. Bellone, S., El-Sahwi, K., Cocco, E., Casagrande, F., Cargnelutti, M., Palmieri, M., Bignotti, E., Romani, C., Silasi, D. A., Azodi, M., Schwartz, P. E., Rutherford, T. J., Pecorelli, S., and Santin, A. D. (2009). Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J. Virol. 83, 6779-6789.
6. Bhat, P., Mattarollo, S. R., Gosmann, C., Frazer, I. H., and Leggatt, G. R. (2011). Regulation of immune responses to HPV infection and during HPV directed immunotherapy. Immunol. Rev. 239, 85-98.
7. Campo, M. S., Graham, S. V., Cortese, M. S., Ashrafi, G. H., Araibi, E. H., Dornan, E. S., Miners, K., Nunes, C., and Man, S. (2010). HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407, 137-142.
8. Cresswell, P., Arunachalam, B., Ban-gia, N., Dick, T., Diedrich, G., Hughes, E., and Maric, M. (1999). Thiol oxidation and reduction in MHC-restricted antigen processing and presentation. Immunol. Res. 19, 191-200.
9. de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U., and zur Hausen, H. (2004). Classification of papillo-maviruses. Virology 324, 17-27.
10. de Vos van Steenwijk, P. J., Heusinkveld, M., Ramwadhdoebe, T. H., Lowik, M. J., van der Hulst, J. M., Goede-mans, R., Piersma, S. J., Kenter, G. G., and van der Burg, S. H. (2010). An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res. 70, 2707-2717.
11. Desaintes, C., Demeret, C., Goyat, S., Yaniv, M., and Thierry, F. (1997). Expression of the papillomavirus E2 protein in HeLa cells leads to apop-tosis. EMBO J. 16, 504-514.
12. Finn, O. J. (2008). Cancer immunology. N. Engl. J. Med. 358, 2704-2715.
13. Frazer, I. H. (2004). Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4, 46-54.
14. Frazer, I. H., Leggatt, G. R., and Mat-tarollo, S. R. (2010). Prevention and treatment of papillomavirus-related cancers through immunization. Annu. Rev. Immunol. 29, 111-138.
15. Hawkins, O. E., Vangundy, R. S., Eck-erd, A. M., Bardet, W., Buchli, R., Weidanz, J. A., and Hildebrand, W. H. (2008). Identification of breast cancer peptide epitopes presented by HLA-A*0201. J. Proteome Res. 7, 1445-1457.
16. Henderson, R. A., Michel, H., Sak-aguchi, K., Shabanowitz, J., Appella, E., Hunt, D. F., and Engelhard, V. H. (1992). HLA-A2.1-associated pep-tides from a mutant cell line: a second pathway of antigen presentation. Science 255, 1264-1266.
17. Heusinkveld, M., Welters, M. J., van Poelgeest, M. I., van der Hulst, J. M., Melief, C. J., Fleuren, G. J., Ken-ter, G. G., and van der Burg, S. H. (2011). The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int. J. Cancer 128, 379-389.
18. Jordanova, E. S., Gorter, A., Ayachi, O., Prins, F., Durrant, L. G., Ken-ter, G. G., van der Burg, S. H., and Fleuren, G. J. (2008). Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin. Cancer Res. 14, 2028-2035.
19. Kawahara, M., Hori, T., Matsubara, Y., Okawa, K., and Uchiyama, T. (2006). Identification of HLA class I-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis. Exp. Hematol. 34, 1496-1504.
20. Kenter, G. G., Welters, M. J., Valentijn, A. R., Lowik, M. J., Berends-van der Meer, D. M., Vloon, A. P., Essah-sah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., van der Burg, S. H., and Melief, C. J. (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithe-lial neoplasia. N. Engl. J. Med. 361, 1838-1847.
21. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., and Schiller, J. T. (1992). Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immuno-genic. Proc. Natl. Acad. Sci. U.S.A. 89, 12180-12184.
22. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R., and Schiller, J. T. (1993). Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67, 6929-6936.
23. Lank, S. M., Wiseman, R. W., Dudley, D. M., and O'Connor, D. H. (2010). A novel single cDNA amplicon pyrosequencing method for high-throughput, cost-effective sequence-based HLA class I genotyping. Hum. Immunol. 71, 1011-1017.
24. Maric, M., Arunachalam, B., Phan, U. T., Dong, C., Garrett, W. S., Cannon, K. S., Alfonso, C., Karlsson, L., Flavell, R. A., and Cresswell, P. (2001). Defective antigen processing in GILT-free mice. Science 294, 1361-1365.
25. Miseta, A., and Csutora, P. (2000). Relationship between the occurrence of cysteine in proteins and the complexity of organisms. Mol. Biol. Evol. 17, 1232-1239.
26. Munger, K., Phelps, W. C., Bubb, V., Howley, P. M., and Schlegel, R. (1989a). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417-4421.
27. Munger, K., Werness, B. A., Dyson, N., Phelps, W. C., Harlow, E., and How-ley, P. M. (1989b). Complex formation of human papillomavirus E7 proteins with the retinoblas-toma tumor suppressor gene product. EMBO J. 8, 4099-4105.
28. Munger, K., Scheffner, M., Huibregtse, J. M., and Howley, P. M. (1992). Interactions of HPV E6 and E7 oncopro-teins with tumour suppressor gene products. Cancer Surv. 12, 197-217.
29. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V., Snijders, P. J., and Meijer, C. J. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348, 518-527.
30. O'Donnell, P. W., Haque, A., Klemsz, M. J., Kaplan, M. H., and Blum, J. S. (2004). Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells is STAT1-dependent but CIITA-independent. J. Immunol. 173, 731-735.
31. Parkin, D. M. (2006). The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044.
32. Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I., Kwappenberg, K. M., van der Hulst, J. M., Dri-jfhout, J. W., Melief, C. J., Ken-ter, G. G., Fleuren, G. J., Offringa, R., and van der Burg, S. H. (2007). High number of intraepithe-lial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metas-tases in patients with large early-stage cervical cancer. Cancer Res. 67, 354-361.
33. Rausch, M. P., Irvine, K. R., Antony, P. A., Restifo, N. P., Cresswell, P., and Hastings, K. T. (2010). GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. J. Immunol. 185, 2828-2835.
34. Reche, P. A., and Reinherz, E. L. (2005). PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res. 33, W138-W142.
35. Reinherz, E. L., and Acuto, O. (2011). Molecular T cell biology-basic and translational challenges in the 21st century. Front. Immunol. 2:3. doi:10.3389/fimmu.2011.00003
36. Reinhold, B., Keskin, D. B., and Rein-herz, E. L. (2010). Molecular detection of targeted major histocom-patibility complex I-bound pep-tides using a probabilistic measure and nanospray MS(3) on a hybrid quadrupole-linear ion trap. Anal. Chem. 82, 9090-9099.
37. Riemer, A., Keskin, D. B., Zhang, G., Handley, M., Anderson, K. S., Bru-sic, V., Reinhold, B., and Rein-herz, E. L. (2010). A conserved E7-derived CTL epitope expressed on human papillomavirus-16 transformed HLA-A2+ human epithelial cancers. J. Biol. Chem. 285, 29608-29622.
38. Robinson, J., Mistry, K., McWilliam, H., Lopez, R., Parham, P., and Marsh,S. G.(2011). The IMGT/HLA database. Nucleic Acids Res. 39, D1171-D1176.
39. Sarid, R., and Gao, S. J. (2011). Viruses and human cancer: from detection to causality. Cancer Lett. 305, 218-227.
40. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
41. Seedorf, K., Krammer, G., Durst, M., Suhai, S., and Rowekamp, W. G. (1985). Human papillomavirus type 16 DNA sequence. Virology 145, 181-185.
42. Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., and Allison, J. P. (2008). Epitope landscape in breast and colorectal cancer. Cancer Res. 68, 889-892.
43. Sidney, J., Grey, H. M., Kubo, R. T., and Sette, A. (1996). Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol. Today 17, 261-266.
44. Singh, R., and Cresswell, P. (2010). Defective cross-presentation of viral antigens in GILT-free mice. Science 328, 1394-1398.
45. Srinivasan, P., and Maric, M. (2011). Signal transducer and activator of transcription 1 negatively regulates constitutive gamma interferon-inducible lysosomal thiol reduc-tase expression. Immunology 132, 209-216.
46. Stanley, M. A., Pett, M. R., and Cole-man,N.(2007). HPV: from infection to cancer. Biochem. Soc. Trans. 35, 1456-1460.
47. Stoler, M. H., Whitbeck, A., Wolinsky, S. M., Broker, T. R., Chow, L. T., Howett, M. K., and Kreider, J. W. (1990). Infectious cycle of human papillomavirus type 11 in human foreskin xenografts in nude mice. J. Virol. 64, 3310-3318.
48. Stone, K. M., Karem, K. L., Sternberg, M. R., McQuillan, G. M., Poon, A. D., Unger, E. R., and Reeves, W. C. (2002). Seroprevalence of human papillomavirus type 16 infection in the United States. J. Infect. Dis. 186, 1396-1402.
49. Sudo, T., Kamikawaji, N., Kimura, A., Date, Y., Savoie, C. J., Nakashima, H., Furuichi, E., Kuhara, S., and Sasazuki, T. (1995). Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J. Immunol. 155, 4749-4756.
50. Terlou, A., Seters, M., Kleinjan, A., Heijmans-Antonissen, C., Sante-goets, L. A., Beckmann, I., Beurden, M., Helmerhorst, T. J., and Blok, L. J. (2010). Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithe-lial neoplasia. Int. J. Cancer 127, 2831-2840.
51. Trimble, C. L., Peng, S., Thoburn, C., Kos, F., and Wu, T. C. (2011). Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol. Immunother. 59, 799-803.
52. van Driel, W. J., Ressing, M. E., Ken-ter, G. G., Brandt, R. M., Krul, E. J., van Rossum, A. B., Schuur-ing, E., Offringa, R., Bauknecht, T., Tamm-Hermelink, A., van Dam, P. A., Fleuren, G. J., Kast, W. M., Melief, C. J., and Trimbos, J. B. (1999). Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35, 946-952.
53. van Seters, M., van Beurden, M., ten Kate, F. J., Beckmann, I., Ewing,P. C., Eijkemans, M. J., Kagie, M. J., Meijer, C. J., Aaronson, N. K., Kleinjan, A., Heijmans-Antonissen, C., Zijlstra, F. J., Burger, M. P., and Helmerhorst, T. J. (2008). Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N. Engl. J. Med. 358, 1465-1473.
54. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kum-mer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., and Munoz, N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19.
55. Wei, M. L., and Cresswell, P. (1992). HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356, 443-446.
56. Weinzierl, A. O., Maurer, D., Altenberend, F., Schneiderhan-Marra, N., Klingel, K., Schoor, O., Wernet, D., Joos, T., Rammensee, H. G., and Stevanovic, S. (2008). A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spec-trometry and T-cell assays. Cancer Res. 68, 2447-2454.
57. Welters, M. J., Kenter, G. G., de Vos van Steenwijk, P. J., Lowik, M. J., Berends-van der Meer, D. M., Essah-sah, F., Stynenbosch, L. F., Vloon, A. P., Ramwadhdoebe, T. H., Piersma, S. J., van der Hulst, J. M., Valentijn, R. P. M., Fathers, L. M., Drijfhout, J. W., Franken, K. M. C., Oosten-dorp, J., Fleuren, G. J., Melief, C. J. M., and van der Burg, S. H. (2010). Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and pheno-type of induced T-cell responses. Proc. Natl. Acad. Sci. U.S.A. 107, 11895-11899.
58. Wilczynski, S. P., Bergen, S., Walker, J., Liao,S. Y.,and Pearlman,L. F. (1988). Human papillomaviruses and cervical cancer: analysis of histopatho-logic features associated with different viral types. Hum. Pathol. 19, 697-704.
59. Yee, C., Krishnan-Hewlett, I., Baker, C. C., Schlegel, R., and Howley, P. M. (1985). Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119, 361-366.
60. Zhang, G. L., Deluca, D. S., Keskin, D. B., Chitkushev, L., Zlateva, T., Lund, O., Reinherz, E. L., and Bru-sic, V. (2010). MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles. J. Immunol. Methods 374, 53-61.
61. zur Hausen, H. (2002). Papillo-maviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2, 342-350.